DHR
DanaherDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bioprocessing and Life Sciences recovery can persist, Diagnostics can stabilize, and the Masimo transaction can improve mix and EPS leverage if regulatory clearance and integration proceed cleanly. If those pieces hold, the stock can move closer to the Street's median target of 264.19 than the current 161.91 anchor price.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Diagnostics remains the weakest segment; Q1 core growth was only 0.5%, and Cepheid's lighter respiratory season highlighted how uneven the recovery still is.
Momentum
18
Value
62
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $168.00 · Bull $205.00 · Bear $132.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $264.19
Why
Momentum18 · Δ7d +6.6
Value62 · Δ7d -0.1
Sentiment44 · Δ7d -1.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
18
34% active weight
Current posture
7d trendImproving
Δ7d
+6.6
Δ21d
+8.6
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
44
33% active weight
Current posture
7d trendSoftening
Δ7d
-1.2
Δ21d
-4.0
Why this grade
Composite grade D. Momentum 18.5 / Value 62.4 / Sentiment 44.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$127.31B
Beta
0.92
Shares Out
706.35M
P/E (TTM)
48.4
P/S (TTM)
6.85
P/FCF (TTM)
39.87
Rev YoY
+4.4%
EPS YoY
+13.4%
Gross Margin
+59.6%
Op Margin
+19.0%
Net Debt
$13.93B
Current Ratio
1.52
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology